At a glance
- Alprostadil is prostaglandin E1, a small lipid signalling molecule rather than a peptide. It is studied as a defined reference for vascular smooth-muscle relaxation, cyclic-AMP signalling, and prostaglandin-receptor biology.
- Approved prescription alprostadil products exist for specific indications and routes. This research vial is not one of those products, and the catalogue category should not be read as proof that alprostadil is a peptide or a clinically interchangeable medicine.
- Use alprostadil as a PGE1 reference in vascular smooth-muscle, receptor, or second-messenger models.
- Measure cyclic AMP and contractile response separately so receptor signalling is not inferred from tissue movement alone.
What ALPROSTADIL is—and what the name does not establish
Alprostadil is prostaglandin E1, a small lipid signalling molecule rather than a peptide. It is studied as a defined reference for vascular smooth-muscle relaxation, cyclic-AMP signalling, and prostaglandin-receptor biology.
Alprostadil engages prostaglandin E receptors and can raise cyclic AMP in responsive smooth-muscle cells. In plain language, the signal can reduce contractile tone, but the response depends on receptor subtype, tissue, concentration, and formulation.
Questions to settle before interpreting a result
A useful ALPROSTADIL study begins with material identity, a defined model, a relevant comparator, and an endpoint chosen before the result is known. Broad catalogue language cannot replace those controls.
- Use alprostadil as a PGE1 reference in vascular smooth-muscle, receptor, or second-messenger models.
- Measure cyclic AMP and contractile response separately so receptor signalling is not inferred from tissue movement alone.
- Control for solvent, temperature, oxidation, and formulation because prostaglandins are chemically sensitive research materials.
How to read the ALPROSTADIL evidence
These evidence snapshots summarize the most important distinctions in the published record. They do not combine unlike models or turn an experimental signal into a human-use claim.
Established pharmacology
- Design
- PGE1 signalling is well characterized in humans
- Finding
- Alprostadil is used in regulated prescription products, giving the active molecule an established pharmacology. Product-specific formulation, route, dose, sterility, and manufacturing controls remain essential to that evidence.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
Catalogue correction
- Design
- This product is a prostaglandin—not a peptide
- Finding
- Its presence in a peptide catalogue is a merchandising convenience. Researchers should classify and handle it according to its actual chemistry rather than the category around it.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
Formulation matters
- Design
- Route-specific products are not interchangeable
- Finding
- Approved alprostadil products use different delivery systems and instructions. Those formulation controls shape exposure and cannot be inferred from a generic vial.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
What the evidence does not establish
Approved prescription alprostadil products exist for specific indications and routes. This research vial is not one of those products, and the catalogue category should not be read as proof that alprostadil is a peptide or a clinically interchangeable medicine.
Mechanism, cell, animal, observational, and controlled human evidence answer different questions. A positive result at one level cannot be silently promoted to another, and evidence for a sponsor’s defined product does not establish equivalence for an independently sourced research material.
Keep the publication and the vial separate
A published paper identifies its own sequence or chemical identity, formulation, manufacturing context, analytical controls, exposure, and test system. Matching a familiar name on a label is not enough to show that a catalogue vial is the same study material.
For practical research planning, verify the lot-specific identity and documentation, then write the model, comparator, endpoint, and stopping criteria before testing. This guide does not provide preparation, dosing, injection, or human-use instructions.
Sources
Links lead to the paper, official registry, regulator page, or product label used for this guide. Registry records describe protocols and status; they are not treated as positive results.
- Caverject (alprostadil) official prescribing informationDailyMed · U.S. National Library of Medicine · Current label
Official label for a regulated alprostadil drug product. Its formulation, route, manufacturing, and clinical evidence do not transfer to a generic catalogue material.
- Think twice before injecting peptides bought online: unauthorized products can seriously harm youHealth Canada · 2026
Official Canadian advisory explaining that a research-use label does not establish authorization, safety, efficacy, or product quality for human use.
Vote for ALPROSTADIL
This compound is not currently stocked. Add it to your five-choice catalogue ballot.